These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 7430635

  • 21. Differential effects of liposome-incorporation on liver macrophage activating potencies of rough lipopolysaccharide, lipid A, and muramyl dipeptide. Differences in susceptibility to lysosomal enzymes.
    Daemen T, Veninga A, Dijkstra J, Scherphof G.
    J Immunol; 1989 Apr 01; 142(7):2469-74. PubMed ID: 2926140
    [Abstract] [Full Text] [Related]

  • 22. Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with concanavalin A.
    Fidler IJ, Darnell JH, Budmen MB.
    Cancer Res; 1976 Oct 01; 36(10):3608-15. PubMed ID: 953987
    [Abstract] [Full Text] [Related]

  • 23. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes.
    Saiki I, Sone S, Fogler WE, Kleinerman ES, Lopez-Berestein G, Fidler IJ.
    Cancer Res; 1985 Dec 01; 45(12 Pt 1):6188-93. PubMed ID: 3933823
    [Abstract] [Full Text] [Related]

  • 24. The in situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process.
    Fidler IJ.
    J Immunol; 1981 Oct 01; 127(4):1719-20. PubMed ID: 6974201
    [No Abstract] [Full Text] [Related]

  • 25. Interferon-induced enhancement of macrophage-mediated tumor cytolysis and its difference from activation by lymphokines.
    Boraschi D, Tagliabue A.
    Eur J Immunol; 1981 Feb 01; 11(2):110-4. PubMed ID: 6163639
    [Abstract] [Full Text] [Related]

  • 26. Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.
    Utsugi T, Sone S.
    J Immunol; 1986 Feb 01; 136(3):1117-22. PubMed ID: 3079797
    [Abstract] [Full Text] [Related]

  • 27. Activation of tumoricidal properties in murine macrophages by intravenous injection of muramyl dipeptide encapsulated within liposomes as a treatment for spontaneous metastasis.
    Fidler IJ, Poste G.
    Prog Clin Biol Res; 1981 Feb 01; 75B():257-67. PubMed ID: 7323097
    [No Abstract] [Full Text] [Related]

  • 28. Activation of murine macrophages. I. Different pattern of activation by poly I:C than by lymphokine or LPS.
    Taramelli D, Varesio L.
    J Immunol; 1981 Jul 01; 127(1):58-63. PubMed ID: 6787132
    [Abstract] [Full Text] [Related]

  • 29. Antitumor and phagocytic activities of rat alveolar macrophage subpopulations separated on a discontinuous gradient of bovine serum albumin.
    Sone S, Key ME.
    J Biol Response Mod; 1986 Dec 01; 5(6):595-603. PubMed ID: 2947976
    [Abstract] [Full Text] [Related]

  • 30. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
    Phillips NC, Chedid L, Bernard JM, Level M, Lefrancier P.
    J Biol Response Mod; 1987 Dec 01; 6(6):678-91. PubMed ID: 3450784
    [Abstract] [Full Text] [Related]

  • 31. Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages.
    Fidler IJ, Raz A, Fogler WE, Kirsh R, Bugelski P, Poste G.
    Cancer Res; 1980 Dec 01; 40(12):4460-6. PubMed ID: 7002293
    [Abstract] [Full Text] [Related]

  • 32. Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages.
    Poste G, Kirsh R.
    Cancer Res; 1979 Jul 01; 39(7 Pt 1):2582-90. PubMed ID: 87267
    [Abstract] [Full Text] [Related]

  • 33. Production of a tumor cytolytic factor(s) by activated human alveolar macrophages and its action.
    Sone S, Tachibana K, Ishii K, Ogawara M, Tsubura E.
    Cancer Res; 1984 Feb 01; 44(2):646-51. PubMed ID: 6692369
    [Abstract] [Full Text] [Related]

  • 34. The activation of tumoricidal properties in human blood monocytes by muramyl dipeptide requires specific intracellular interaction.
    Fogler WE, Fidler IJ.
    J Immunol; 1986 Mar 15; 136(6):2311-7. PubMed ID: 2936824
    [Abstract] [Full Text] [Related]

  • 35. In vitro activation of mouse macrophages by rat lymphocyte mediators.
    Fidler IJ, Darnell JH, Budmen MB.
    J Immunol; 1976 Aug 15; 117(2):666-73. PubMed ID: 950467
    [Abstract] [Full Text] [Related]

  • 36. Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL).
    Phillips NC, Moras ML, Chedid L, Petit JF, Tenu JP, Lederer E, Bernard JM, Lefrancier P.
    J Biol Response Mod; 1985 Oct 15; 4(5):464-74. PubMed ID: 3935756
    [Abstract] [Full Text] [Related]

  • 37. Macrophage activation by muramyl dipeptide (MDP) without lymphocyte participation.
    Nagao S, Miki T, Tanaka A.
    Microbiol Immunol; 1981 Oct 15; 25(1):41-50. PubMed ID: 7253958
    [Abstract] [Full Text] [Related]

  • 38. Preparation and antitumor effect of macrophage activating factor (MAF) encapsulated in liposomes bearing a monoclonal anti-human melanoma (A375) antibody.
    Watanabe Y, Uchida E, Higuchi M, Imai Y, Osawa T.
    J Biol Response Mod; 1987 Oct 15; 6(5):556-68. PubMed ID: 3316511
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of mitogen-induced polyclonal activation by by a synthetic adjuvant, muramyl dipeptide (MDP).
    Löwy I, Leclerc C, Bourgeois E, Chedid L.
    J Immunol; 1980 Jan 15; 124(1):320-5. PubMed ID: 6985643
    [Abstract] [Full Text] [Related]

  • 40. Macrophage activation by muramyl dipeptide bound to neoglycoproteins and glycosylated polymers: cytotoxic factor production.
    Petit C, Monsigny M, Roche AC.
    J Biol Response Mod; 1990 Feb 15; 9(1):33-43. PubMed ID: 2319259
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.